These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38088203)

  • 1. Analysis of iron status after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.
    James A; Li G; List R; Lonabaugh K; Smith AD; Barros A; Somerville L; Albon D
    Pediatr Pulmonol; 2024 Mar; 59(3):669-678. PubMed ID: 38088203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series.
    Vonk SEM; Lub R; Weersink EJM; Beuers U; Mathôt RAA; Kemper EM; Altenburg J;
    Clin Ther; 2024 Feb; 46(2):154-158. PubMed ID: 38042631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease.
    Burgel PR; Paillasseur JL; Durieu I; Reynaud-Gaubert M; Hamidfar R; Murris-Espin M; Danner-Boucher I; Chiron R; Leroy S; Douvry B; Grenet D; Mely L; Ramel S; Montcouquiol S; Burnet E; Ouaalaya EH; Sogni P; Da Silva J; Martin C;
    Ann Am Thorac Soc; 2024 Jul; 21(7):1053-1064. PubMed ID: 38579175
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of elexacaftor/tezacaftor/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis.
    Dittrich AM; Sieber S; Naehrlich L; Burkhart M; Hafkemeyer S; Tümmler B;
    Int J Infect Dis; 2024 Feb; 139():124-131. PubMed ID: 38036261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.
    Nichols DP; Paynter AC; Heltshe SL; Donaldson SH; Frederick CA; Freedman SD; Gelfond D; Hoffman LR; Kelly A; Narkewicz MR; Pittman JE; Ratjen F; Rosenfeld M; Sagel SD; Schwarzenberg SJ; Singh PK; Solomon GM; Stalvey MS; Clancy JP; Kirby S; Van Dalfsen JM; Kloster MH; Rowe SM;
    Am J Respir Crit Care Med; 2022 Mar; 205(5):529-539. PubMed ID: 34784492
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
    Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
    Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.
    Scully KJ; Marchetti P; Sawicki GS; Uluer A; Cernadas M; Cagnina RE; Kennedy JC; Putman MS
    J Cyst Fibros; 2022 Mar; 21(2):258-263. PubMed ID: 34531155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy.
    Miller JE; Taylor-Cousar JL; Overdevest JB; Khatiwada A; Mace JC; Alt JA; Bodner TE; Chowdhury NI; DiMango EA; Eshaghian PH; Getz AE; Gudis DA; Han EJ; Hwang PH; Keating CL; Khanwalkar A; Kimple AJ; Lee JT; Li D; Markarian K; Norris M; Nayak JV; Owens C; Patel ZM; Poch K; Schlosser RJ; Smith KA; Smith TL; Soler ZM; Suh JD; Tervo JP; Turner GA; Wang MB; Saavedra MT; Beswick DM
    Int Forum Allergy Rhinol; 2024 Jun; 14(6):1079-1087. PubMed ID: 38145393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of elexacaftor/tezacaftor/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index.
    Patel T; McBennett K; Sankararaman S; Schindler T; Sundaram K; Minich NM; Malay S; Kutney K
    Pediatr Pulmonol; 2024 Mar; 59(3):734-742. PubMed ID: 38179878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fetal drug exposure after maternally administered CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor in a rat model.
    Li D; Zhu Y; Donnelley M; Parsons D; Habgood MD; Schneider-Futschik EK
    Biomed Pharmacother; 2024 Feb; 171():116155. PubMed ID: 38232663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
    Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elexacaftor/tezacaftor/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction study.
    van der Meer R; Wilms EB; Eggermont MN; Paalvast HM; van Luin M; van Rossen RCJM; Heijerman HGM
    J Cyst Fibros; 2024 May; 23(3):549-553. PubMed ID: 38290918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients.
    Ramos KJ; Guimbellot JS; Valapour M; Bartlett LE; Wai TH; Goss CH; Pilewski JM; Faro A; Diamond JM;
    J Cyst Fibros; 2022 Sep; 21(5):745-752. PubMed ID: 35474016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events.
    Ramsey B; Correll CU; DeMaso DR; McKone E; Tullis E; Taylor-Cousar JL; Chu C; Volkova N; Ahluwalia N; Waltz D; Tian S; Mall MA
    Am J Respir Crit Care Med; 2024 Feb; 209(3):299-306. PubMed ID: 37890129
    [No Abstract]   [Full Text] [Related]  

  • 16. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
    N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Series: Hyperbilirubinemia under elexacaftor/tezacaftor/ivacaftor in the presence of Gilbert's syndrome.
    Weitzel J; Welsner M; Taube C; Ballmann M; Sutharsan S
    BMC Pulm Med; 2024 Jul; 24(1):307. PubMed ID: 38956524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Elexacaftor-Tezacaftor-Ivacaftor on lung disease in cystic fibrosis.
    Gushue C; Eisner M; Bai S; Johnson T; Holtzlander M; McCoy K; Sheikh S
    Pediatr Pulmonol; 2023 Aug; 58(8):2308-2316. PubMed ID: 37222417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients.
    Klimeš F; Voskrebenzev A; Gutberlet M; Speth M; Grimm R; Dohna M; Hansen G; Wacker F; Renz DM; Dittrich AM; Vogel-Claussen J
    Eur Radiol; 2024 Jan; 34(1):80-89. PubMed ID: 37548691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Questions and Answers? Depression Symptoms Associated with Elexacaftor/Tezacaftor/Ivacaftor Treatment for Cystic Fibrosis.
    Lee TWR; Duff AJA
    Am J Respir Crit Care Med; 2024 Feb; 209(3):239-241. PubMed ID: 38113403
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.